Pancreatic cancer trial combines chemo with immune boosters

NCT ID NCT03727880

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy before and after surgery could help the body fight pancreatic cancer better. It involved 28 people with early-stage, removable pancreatic cancer. The goal was to see if this combination could shrink tumors more effectively and improve long-term outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Samuel Oschin Cancer Center at Cedars-Sinai

    Los Angeles, California, 90048, United States

  • Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21231, United States

  • The University of Texas Health Science Center San Antonio

    San Antonio, Texas, 78229, United States